Nuvalent fetches $50m Series A

Nuvalent Inc, a creator of precisely targeted therapies for clinically proven kinase targets in cancer, has secured $50 million in Series A financing.

Nuvalent Inc, a creator of precisely targeted therapies for clinically proven kinase targets in cancer, has secured $50 million in Series A financing. The backer was Deerfield Management.

Source: Press Release